RSV poses a health threat to some older adults, prompting CDC's call for vaccination and Medicare's assurance of coverage of ...

Earlier in October, Pfizer Inc (NYSE: PFE ... budget by $1.1 billion over the next three years while it aims to get FDA ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

Novavax has received the green light from the US Food and Drug Administration (FDA) to resume clinical trials for its ...

Novavax has struggled to keep pace with rival vaccine makers Moderna and Pfizer, which reported more than $3 billion ...

There is no evidence Japan has named the COVID-19 vaccine the “most deadly drug in history,” as the post claims.

The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...

The Food and Drug Administration has cleared Novavax to move forward with testing of a combination vaccine for COVID-19 and ...

The other group at the highest risk when it comes to RSV is children under age five, and specifically infants—especially ...

Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, ...